Atlas Trials

Hunter Syndrome

26 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hunter Syndrome

RecordFirmDate
A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India (NCT05058391)Takeda2022-04-21
MPS II Immunophenotyping (NCT04976231)Duke University2022-04-01
Biomarkers for Hunter Syndrome (NCT01330277)CENTOGENE GmbH Rostock2018-08-20
An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) (NCT07344376)GC Biopharma Corp2018-05-23
Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) (NCT03582449)Shire2018-01-19
A Study of GC1111 in Hunter Syndrom Patients (NCT03920540)Green Cross Corporation2017-03-09
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age (NCT02455622)Shire2015-10-28
Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094 (NCT02412787)Shire2015-04-14
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis (NCT02171104)Masonic Cancer Center, University of Minnesota2014-07-10
The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients (NCT02044692)Green Cross Corporation2014-01-01
Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) (NCT01822184)Shire2013-01-18
Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome (NCT01449240)Shire2012-11-12
Safety and Efficacy of Hunterase (NCT01645189)Green Cross Corporation2012-07-01
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment (NCT01506141)Takeda2010-08-01
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders (NCT01043640)Masonic Cancer Center, University of Minnesota2009-12-01
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® (NCT00920647)Shire2009-11-18
Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® (NCT00937794)Shire2009-07-02
An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients (NCT00882921)Shire2008-10-14
Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy (NCT00607386)Shire2007-12-31
Hunter Outcome Survey (HOS) (NCT03292887)Shire2005-10-03
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase (NCT00630747)Shire2004-09-13
Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome (NCT05795361)Takeda

Track Hunter Syndrome automatically

Every clearance here is in the API, with alerts when new ones post.